Dec 9, 2019 8:30 am EST Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues
Oct 30, 2019 8:30 am EDT Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists
Oct 15, 2019 8:35 am EDT Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
Oct 15, 2019 8:30 am EDT Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
Oct 3, 2019 8:30 am EDT Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting
Aug 27, 2019 8:30 am EDT Emerald Bioscience to Participate in Investment and Scientific Conferences in September
Aug 26, 2019 8:30 am EDT Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
Aug 13, 2019 8:30 am EDT Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study